According to World Health Organization (WHO) current updates, the COVID-19 pandemic has spread all over the globe affecting 216 countries and caused 8,860,331 confirmed cases and 465,740 deaths last followed by 24 June 2020. Many countries cannot afford the nucleic acid tests to confirm COVID-19 infected patients; as a result, people cannot know the COVID-19 status of the people living around them. The use of dexamethasone in COVID-19 hospitalized patients for up to 10 days lower 28-day mortality as compared to the patients taking usual care and also receiving mechanical ventilation at randomization (by age-adjusted percentage points 12.3, approximately one third of proportional reduction) and those patients receiving oxygen without invasive mechanical ventilation (by age-adjusted percentage points 4.1, approximately one fifth of proportional reduction).
The author(s) received no specific funding for this work.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Khan, Muhammad Arif; Ullah, Ikram; and Ahmed, Dawood
"COVID-19 and the Unseen Benefits of Dexamethasone,"
The University of Louisville Journal of Respiratory Infections: Vol. 4
, Article 66.
Available at: https://ir.library.louisville.edu/jri/vol4/iss1/66